36.44
price down icon3.14%   -1.18
after-market アフターアワーズ: 36.34 -0.10 -0.27%
loading
前日終値:
$37.62
開ける:
$37.37
24時間の取引高:
3.14M
Relative Volume:
0.55
時価総額:
$42.46B
収益:
$17.53B
当期純損益:
$1.58B
株価収益率:
27.08
EPS:
1.3457
ネットキャッシュフロー:
$444.18M
1週間 パフォーマンス:
-2.41%
1か月 パフォーマンス:
+15.06%
6か月 パフォーマンス:
+7.62%
1年 パフォーマンス:
+102.00%
1日の値動き範囲:
Value
$36.37
$37.42
1週間の範囲:
Value
$36.37
$38.37
52週間の値動き範囲:
Value
$17.94
$38.37

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Name
名前
Teva Pharmaceutical Industries Ltd Adr
Name
セクター
Healthcare (1080)
Name
電話
972 (3) 914-8213
Name
住所
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Name
職員
32,842
Name
Twitter
@TevaUSA
Name
次回の収益日
2026-07-29
Name
最新のSEC提出書
Name
TEVA's Discussions on Twitter

Compare TEVA vs TAK, HLN, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
36.44 42.89B 17.53B 1.58B 444.18M 1.3457
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.03 57.90B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
10.11 43.41B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
77.34 31.00B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
515.46 22.35B 3.17B 1.29B 1.01B 27.09

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-12-09 開始されました Barclays Overweight
2025-12-05 開始されました Scotiabank Sector Outperform
2025-06-06 開始されました Goldman Buy
2025-05-28 開始されました Truist Buy
2025-05-12 アップグレード JP Morgan Neutral → Overweight
2024-07-10 アップグレード Argus Hold → Buy
2024-03-08 アップグレード JP Morgan Underweight → Neutral
2024-02-12 アップグレード Piper Sandler Neutral → Overweight
2024-01-23 アップグレード Jefferies Hold → Buy
2024-01-03 アップグレード Piper Sandler Underweight → Neutral
2023-12-18 開始されました HSBC Securities Buy
2023-11-27 アップグレード UBS Neutral → Buy
2023-07-06 アップグレード UBS Sell → Neutral
2023-05-25 開始されました Morgan Stanley Equal-Weight
2023-05-18 アップグレード Evercore ISI In-line → Outperform
2023-01-19 ダウングレード Jefferies Buy → Hold
2022-11-14 ダウングレード JP Morgan Neutral → Underweight
2022-11-04 ダウングレード UBS Neutral → Sell
2022-10-21 再開されました Jefferies Buy
2022-08-05 アップグレード BofA Securities Neutral → Buy
2022-06-14 再開されました UBS Neutral
2022-05-17 アップグレード BofA Securities Underperform → Neutral
2022-05-04 ダウングレード Piper Sandler Neutral → Underweight
2022-04-05 アップグレード Barclays Equal Weight → Overweight
2022-03-25 アップグレード Bernstein Mkt Perform → Outperform
2022-01-27 ダウングレード Argus Buy → Hold
2021-10-28 ダウングレード Raymond James Outperform → Mkt Perform
2021-05-04 ダウングレード UBS Buy → Neutral
2021-04-07 再開されました RBC Capital Mkts Sector Perform
2020-11-25 開始されました Oppenheimer Perform
2020-08-06 アップグレード Barclays Underweight → Equal Weight
2020-07-27 再開されました Goldman Neutral
2020-06-01 アップグレード SunTrust Hold → Buy
2020-04-24 再開されました Citigroup Neutral
2020-04-06 アップグレード UBS Neutral → Buy
2020-02-24 ダウングレード Edward Jones Hold → Sell
2019-11-12 アップグレード JP Morgan Underweight → Neutral
2019-10-17 アップグレード Gabelli & Co Hold → Buy
2019-08-07 ダウングレード Evercore ISI Outperform → In-line
2019-07-19 開始されました Wolfe Research Peer Perform
2019-07-15 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-07-10 再開されました Credit Suisse Neutral
2019-07-05 アップグレード Argus Hold → Buy
2019-06-11 開始されました Barclays Underweight
2019-06-03 アップグレード Oppenheimer Perform → Outperform
2019-05-30 ダウングレード BofA/Merrill Buy → Underperform
2019-05-28 ダウングレード UBS Buy → Neutral
2019-03-20 開始されました SunTrust Hold
2019-03-07 再開されました UBS Buy
すべてを表示

Teva Pharmaceutical Industries Ltd Adr (TEVA) 最新ニュース

pulisher
Aug 21, 2026

Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate - Sahm

Aug 21, 2026
pulisher
Aug 19, 2026

TEVA Stock Quote Price and Forecast - CNN

Aug 19, 2026
pulisher
Aug 19, 2026

Teva receives FDA priority review for Tourette drug - grafa.com

Aug 19, 2026
pulisher
Aug 19, 2026

ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView

Aug 19, 2026
pulisher
Aug 18, 2026

Teva Pharmaceutical’s stock is near its yearly high; is it still a buy? - Investing.com Nigeria

Aug 18, 2026
pulisher
Aug 17, 2026

TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing (Aug 17, 2026) - Stock Titan

Aug 17, 2026
pulisher
Aug 14, 2026

TEVA Stock Price, Quote & Chart - ChartMill

Aug 14, 2026
pulisher
Aug 13, 2026

Teva stock hits 52-week high at 37.35 USD By Investing.com - Investing.com Nigeria

Aug 13, 2026
pulisher
Aug 13, 2026

Teva stock hits 52-week high at 37.35 USD - Investing.com

Aug 13, 2026
pulisher
Aug 11, 2026

Moody’s upgrades Teva rating to investment grade on debt cuts By Investing.com - Investing.com Canada

Aug 11, 2026
pulisher
Aug 08, 2026

Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open - Sahm

Aug 08, 2026
pulisher
Aug 05, 2026

Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum - Sahm

Aug 05, 2026
pulisher
Aug 01, 2026

Teva Earnings: Innovation Engine Continues Firing and Supports Our Increased Moat Rating - Morningstar

Aug 01, 2026
pulisher
Jul 31, 2026

July 2026's Top Stock Selections Estimated Below Intrinsic Value - Sahm

Jul 31, 2026
pulisher
Jul 30, 2026

Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There? - Sahm

Jul 30, 2026
pulisher
Jul 29, 2026

Teva seeks clarity on Trump drug tariff plans, CEO says By Investing.com - Investing.com South Africa

Jul 29, 2026
pulisher
Jul 28, 2026

Why Is Teva (NYSE:TEVA) Making NYSE Composite Headlines? - Kalkine Media

Jul 28, 2026
pulisher
Jul 27, 2026

Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma

Jul 27, 2026
pulisher
Jul 25, 2026

Teva Pharmaceutical Industries Limited Sponsored ADR Revenue Breakdown – BX:TEV - TradingView

Jul 25, 2026
pulisher
Jul 25, 2026

Does Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run? - Sahm

Jul 25, 2026
pulisher
Jul 24, 2026

Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK

Jul 24, 2026
pulisher
Jul 24, 2026

Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jul 24, 2026
pulisher
Jul 17, 2026

What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders - Sahm

Jul 17, 2026
pulisher
Jul 14, 2026

MINT,TEVA Volatility & Greeks - Finviz

Jul 14, 2026
pulisher
Jul 14, 2026

Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm

Jul 14, 2026
pulisher
Jul 11, 2026

Teva (TEVA) Stock Looks Reasonable Even With A 48% Gap - Sahm

Jul 11, 2026
pulisher
Jul 10, 2026

Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress - Sahm

Jul 10, 2026
pulisher
Jul 09, 2026

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool

Jul 09, 2026
pulisher
Jul 09, 2026

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis - Sahm

Jul 09, 2026
pulisher
Jul 08, 2026

Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial - Sahm

Jul 08, 2026
pulisher
Jul 07, 2026

Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment - Investing.com

Jul 07, 2026
pulisher
Jul 06, 2026

Teva stock leans on its generic drug base. - Ad-hoc-news.de

Jul 06, 2026
pulisher
Jul 05, 2026

883035 Forecast — Price Target — Prediction for 2027 - TradingView

Jul 05, 2026
pulisher
Jul 03, 2026

TEVATeva- Pharmaceutical Industries Ltd ADR Latest SEC Filings - Finviz

Jul 03, 2026
pulisher
Jul 02, 2026

How Teva’s Ecopipam NDA for Pediatric Tourette Syndrome (TEVA) Has Changed Its Investment Story - Sahm

Jul 02, 2026
pulisher
Jul 01, 2026

India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research

Jul 01, 2026
pulisher
Jun 28, 2026

Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView

Jun 28, 2026
pulisher
Jun 26, 2026

TEV Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

TEVA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

TEVA/N Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView

Jun 26, 2026
pulisher
Jun 25, 2026

Enterprise value to EBITDA forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR - TradingView

Jun 25, 2026
pulisher
Jun 24, 2026

Teva Pharmaceutical Industries Limited Sponsored ADR - TradingView

Jun 24, 2026
pulisher
Jun 23, 2026

TEVA News | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill

Jun 23, 2026
pulisher
Jun 23, 2026

Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth - TradingView

Jun 23, 2026
pulisher
Jun 22, 2026

Why Is Teva Pharmaceutical (NYSE:TEVA) Drawing NYSE Composite Attention? - Kalkine Media

Jun 22, 2026
pulisher
Jun 21, 2026

Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback - Sahm

Jun 21, 2026
pulisher
Jun 19, 2026

Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome - Yahoo Finance

Jun 19, 2026

Teva Pharmaceutical Industries Ltd Adr (TEVA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Teva Pharmaceutical Industries Ltd Adr (TEVA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Weiss Amir
Chief Accounting Officer
Aug 21 '26
Sale
37.62
9,445
355,301
13,071
Satchi-Fainaro Ronit
Director
Aug 21 '26
Sale
37.25
415
15,459
111,986
Lippman Evan
EVP, Business Development
Aug 17 '26
Sale
36.57
18,600
680,291
25,591
HLN HLN
$10.11
price up icon 0.70%
ZTS ZTS
$77.34
price up icon 3.09%
TAK TAK
$18.03
price up icon 0.00%
$515.46
price down icon 2.36%
$16.34
price down icon 3.26%
大文字化:     |  ボリューム (24 時間):